The DNA Damage Response Therapeutics Summit provided a comprehensive analysis of the fundamental science and clinical development process in this space, leveraging collective expert knowledge to optimize the identification and therapeutic exploitation of robust synthetic lethal pairs.
The DNA Damage Response Therapeutics Summit provided an unparalleled opportunity for world leaders to share unique insights and collaborate to overcome barriers in drug development.
Companies that took part included:
AstraZeneca – Tesaro – Novartis – Artios Pharma – MetaboMed – Repare Therapeutics – Sierra Oncology – Epizyme – Broad Institute – Netherlands Cancer Institute – Harvard Medical School – Massachusetts General Hospital – University of Toronto – UT Southwestern – University of Maryland
Gain Unique Insights into the Key Issues Facing This Industry
|1. Achieving Efficacy across Contexts:|
|Define the key steps required to identify & therapeutically exploit robust synthetic lethal interactions that are conserved across a variety of defined contexts.|
|2. Optimize Patient Stratification:|
|Streamline clinical trials by improving the recruitment & stratification of patients, increasing efficiency.|
|3. Apply Lessons Learned from PARP Inhibitors:|
|Analyze key aspects of the development of PARP inhibitors through case studies, and determine how we can use these insights to advance R&D of new synthetic lethal drugs.|
|4. Exploit Key Targets of Mechanisms of Resistance:|
|Assess the most effective methods for identifying and utilizing mechanisms of resistance to optimize cancer treatment.|
|5. Harnessing Bioinformatics & Computational Approaches:|
|Exploring the latest advances in identifying clinically relevant synthetic lethal interactions from genome wide screens.|